Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

Aliment Pharmacol Ther. 2015 Sep;42(6):696-706. doi: 10.1111/apt.13316. Epub 2015 Jul 22.


Background: The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden.

Aim: A modelling approach was used to quantify the current HCV-infected population, future disease progression and associated costs in Egypt.

Methods: Direct healthcare costs were calculated from a nationally representative hospital and a disability adjusted life year (DALY) template was used with monetary value assigned to lost life years. Three scenarios were considered: (i) Historical treatment scenario: 50% SVR; 65,000 treated annually, (ii) Current treatment scenario: 90% sustained virologic response (SVR); 65,000 treated annually, (iii) Increased treatment scenario: 90% SVR; 325,000 treated annually by 2018.

Results: Cumulative DALYs (2015-2030) under Scenario 1 were estimated at 7.88 million and cumulative costs estimated at $89.07 billion. Annual DALYs increased 16% during 2015-2030 while annual costs more than doubled. Scenario 2 reduced cumulative DALYs and costs by 7% and 4%, respectively. Under Scenario 3, total costs declined 73% to $1047 million during 2015-2030. As compared to Scenario 1, cumulative DALYs and costs decreased 37% and 35%, respectively.

Conclusions: This is the first estimate of the total economic burden of HCV in Egypt. Extraordinary measures are necessary to substantially reduce HCV disease and cost burden. With newer therapies, strategies to reduce disease burden are feasible and cost-effective.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disabled Persons
  • Disease Progression
  • Egypt / epidemiology
  • Health Expenditures / statistics & numerical data*
  • Hepatitis C / economics*
  • Hepatitis C / therapy*
  • Humans
  • Models, Econometric
  • Prevalence
  • Quality-Adjusted Life Years